Akebia Therapeutics (AKBA) Reports In-Line Q3 EPS

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $40.12 million versus the consensus estimate of $49.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings